IMPLANET Reports Revenue of €4.1 Million in the First Half of 2024
- Continued growth momentum in the French market
- Strong progress in medical equipment sales, +81% vs. H1 2023
Financial information for the First Half of 2024
Revenue (in € thousands – IFRS)1 |
H1 2024 |
H1 2023 |
Change % |
|
|
|
|
|
2,071 |
1,788 |
+16% |
|
479 |
818 |
-41% |
Rest of the world |
1,093 |
1,334 |
-18% |
Spine revenue |
3,643 |
3,940 |
-8% |
Medical equipment (SMTP) |
455 |
250 |
+81% |
Services (MADISONTM) |
19 |
78 |
-75% |
Total revenue for the first half |
4,117 |
4,268 |
-4% |
Spine activity generated revenue of €3.64 million in the first half of 2024, down 8% compared with revenue of €3.94 million in the first half of 2023.
Spine activity in
The Company is also continuing the rollout of its medical equipment distribution activity, with commercialization in
In total,
Financial information for the Second Quarter of 2024
Revenue (in € thousands – IFRS)2 |
Q2 2024 |
Q2 2023 |
Change % |
|
|
|
|
|
1,039 |
846 |
+23% |
|
165 |
359 |
-54% |
Rest of the world |
475 |
660 |
-28% |
Spine revenue |
1,679 |
1,865 |
-10% |
Medical equipment (SMTP) |
208 |
127 |
+64% |
Services (MADISONTM) |
7 |
69 |
-90% |
Total revenue for the second quarter |
1,894 |
2,060 |
-8% |
Spine activity generated revenue of €1.68 million in the second quarter of 2024, down 10% compared with revenue of €1.86 million in the second quarter of 2023.
Activity in
Finally, revenue generated in the distribution of medical equipment in the second quarter of 2024 amounted to €0.21 million, i.e. 64% increase compared to the €0.13 million recorded in the same period the previous year.
Total revenue recorded in the second quarter of 2024 thus reached €1.89 million, compared to €2.06 million for the same period last year.
Cash position
As of
The remaining balance of the sale of the MADISONTM activity, amounting to €0.85 million, is expected to be received as follows: €0.68 million in Q3 2024 and €0.17 million in the first half of 2025.
The Company is also exploring the implementation of payment facilities with the Sanyou Medical group.
In view of these elements and the cash consumption forecasts based on current activity assumptions and anticipated business developments with Sanyou Medical over the 2024 and 2025 financial years, the Company considers that it will be able to cover the financing requirements of its operations for the next twelve months.
Key events in the First Half of 2024
-
Successful completion of the capital increase announced on
January 4, 2024 , raising €5.5 million through the issuance of 83,924,897 new shares; -
Appointment of
Max W. Painter as Vice President and General Manager of IMPLANET’s US subsidiary; -
FDA clearance of the new Jazz Spinal SystemTM hybrid posterior fixation range in
the United States .
2024 strategy and outlook
- Finalize the registration of existing products within the framework of the European Medical Device Regulation (MDR).
-
Reinvigorate the Company’s presence in
the United States :- Strengthen the resources and commercial means available to the historical team;
- Strengthen the Company’s direct approach by expanding the scientific team of opinion leaders.
-
Strengthen market momentum and the product offering:
- Deploy the commercial and technological partnership with Sanyou Medical to jointly develop an innovative new European range of hybrid posterior fixation;
-
Initiate the distribution of the JAZZ® platform in
China (the world’s largest spine market by volume) with Sanyou Medical; -
Distribute technological medical equipment in
Europe , such as the ultrasound surgical scalpel fromSMTP Technology Co.
Upcoming financial event:
-
2024 first-half results, on
September 10, 2024 , after market close
About
Founded in 2007,
For further information, please visit www.Implanet.com.
1
Unaudited figures
2
Unaudited figures
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709077250/en/
Tél. : +33 (0)5 57 99 55 55
investors@Implanet.com
NewCap
Investor Relations
Nicolas Fossiez
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu
NewCap
Media Relations
Arthur Rouillé
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu
Source: